How do doctors guide their patients to work effectively despite the breathing disorder or seek modifications to their job ...

COPD encompasses both extremes of weight. Obesity affects some 54% of patients in the U.S., but underweight is also an issue, affecting anywhere from 4% to 40% across populations, with ...

Dear Quentin, My husband is considering contesting his brother’s will. Around 30 days before passing, his brother changed ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

U.S. News & World Report evaluated more than 4,400 hospitals, and only 13% of evaluated hospitals earned a Best Hospitals designation.

We spoke with endocrinologists to explore the potential of artificial intelligence in the management of chronic disease, including diabetes, obesity, and PCOS.

NEW ORLEANS – Ochsner Medical Center – New Orleans, which includes Ochsner Medical Center – West Bank, Ochsner Baptist, and ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Adults over 50 and those with chronic conditions are at risk too. Learn how to protect yourself and where to go for more information.

Select your location to view local American Lung Association events and news near you.

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.